RCMU
JAZZ icon

Rokos Capital Management (UK)’s Jazz Pharmaceuticals JAZZ Stock Holding History

Rokos Capital Management (UK)’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-52,017
Closed -$9.83M – 226
2026
Q1 		$9.83M Buy
+52,017
New +$9.09M 0.07% 120
2023
Q4 		– Sell
-183,109
Closed -$23.9M – 98
2023
Q3 		$23.9M Hold
183,109
– – 0.17% 54
2023
Q2 		$22.7M Buy
+183,109
New +$24.6M 0.22% 43

Other funds holding JAZZ

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return

Rokos Capital Management (UK)'s JAZZ Position: Q2 2026 in Review

Rokos Capital Management (UK) sold out of Jazz Pharmaceuticals (JAZZ) in Q2 2026, closing a stake of 52,017 shares — an estimated $9.83M sold.

Rokos Capital Management (UK) first reported a position in JAZZ in Q2 2023 and held it in 3 quarters. The position peaked at $23.9M in Q3 2023. 641 funds tracked by Wall St. Rank hold JAZZ as of Q2 2026.

  • Rokos Capital Management (UK) reported no remaining Jazz Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Rokos Capital Management (UK) sold 52,017 Jazz Pharmaceuticals shares in Q2 2026, an estimated $9.83M.
  • Rokos Capital Management (UK) first reported a position in Jazz Pharmaceuticals in Q2 2023 and held it in 3 quarters.
  • Rokos Capital Management (UK)'s Jazz Pharmaceuticals position peaked at $23.9M in Q3 2023.
  • 641 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q2 2026.

Based on Rokos Capital Management (UK)'s 13F filing for Q2 2026, filed 14 Aug 2026.